Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.

Launay O, Sadorge C, Jolly N, Poirier B, Béchet S, van der Vliet D, Seffer V, Fenner N, Dowling K, Giemza R, Johnson J, Ndiaye A, Vray M, Sansonetti P, Morand P, Poyart C, Lewis D, Gougeon ML.

Vaccine. 2009 Feb 18;27(8):1184-91. doi: 10.1016/j.vaccine.2008.12.021. Epub 2009 Jan 9.

PMID:
19135496
2.

Live-attenuated Shigella vaccines.

Venkatesan MM, Ranallo RT.

Expert Rev Vaccines. 2006 Oct;5(5):669-86. Review.

PMID:
17181440
3.

Shigellosis: the current status of vaccine development.

Kweon MN.

Curr Opin Infect Dis. 2008 Jun;21(3):313-8. doi: 10.1097/QCO.0b013e3282f88b92. Review.

PMID:
18448978
4.

Analysis and genetic manipulation of Shigella virulence determinants for vaccine development.

Mills SD, Sekizaki T, Gonzalez-Carrero MI, Timmis KN.

Vaccine. 1988 Apr;6(2):116-22. Review.

PMID:
3291449
5.

Shigellosis.

Niyogi SK.

J Microbiol. 2005 Apr;43(2):133-43. Review.

6.

Bivalent cholera and typhoid vaccine.

Foster RH, Noble S.

Drugs. 1999 Jul;58(1):91-6; discussion 97-8. Review.

PMID:
10439932
7.

Vibrio cholerae CVD103-HgR live oral attenuated vaccine: construction, safety, immunogenicity, excretion and non-target effects.

Cryz SJ Jr, Kaper J, Tacket C, Nataro J, Levine MM.

Dev Biol Stand. 1995;84:237-44. Review.

PMID:
7796960
8.

The human rotavirus vaccine RIX4414 in infants: a review of safety and tolerability.

Cheuvart B, Friedland LR, Abu-Elyazeed R, Han HH, Guerra Y, Verstraeten T.

Pediatr Infect Dis J. 2009 Mar;28(3):225-32. doi: 10.1097/INF.0b013e31819715fa. Review.

PMID:
19209095
9.

Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.

Viret JF, Dietrich G, Favre D.

Vaccine. 2004 Jun 23;22(19):2457-69. Review.

PMID:
15193410
10.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
11.

Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Levine MM, Kotloff KL, Barry EM, Pasetti MF, Sztein MB.

Nat Rev Microbiol. 2007 Jul;5(7):540-53. Review.

12.

Biosafety evaluation of recombinant live oral bacterial vaccines in the context of European regulation.

Favre D, Viret JF.

Vaccine. 2006 May 1;24(18):3856-64. Epub 2005 Aug 2. Review.

PMID:
16115705
13.

Oral typhoid vaccine. Acambis/Berna.

Witherell GW.

Curr Opin Investig Drugs. 2003 Aug;4(8):1010-8. Review.

PMID:
14508886
14.

IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.

Kennedy JS, Greenberg RN.

Expert Rev Vaccines. 2009 Jan;8(1):13-24. doi: 10.1586/14760584.8.1.13. Review.

PMID:
19093767
15.

CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression.

Tacket CO, Levine MM.

Clin Infect Dis. 2007 Jul 15;45 Suppl 1:S20-3. Review.

PMID:
17582563
16.

Current aspects of Shigella pathogenesis.

Torres AG.

Rev Latinoam Microbiol. 2004 Jul-Dec;46(3-4):89-97. Review.

PMID:
17061529
17.

Lipopolysaccharide: a tool and target in enterobacterial vaccine development.

Nagy G, Pál T.

Biol Chem. 2008 May;389(5):513-20. Review.

PMID:
18953717
18.

Linear IgA dermatosis: report of an infantile case and analysis of 213 cases in Japan.

Horiguchi Y, Ikoma A, Sakai R, Masatsugu A, Ohta M, Hashimoto T.

J Dermatol. 2008 Nov;35(11):737-43. doi: 10.1111/j.1346-8138.2008.00561.x. Review.

PMID:
19120770

Supplemental Content

Support Center